ADC Therapeutics (ADCT) Competitors $4.16 -0.10 (-2.35%) Closing price 10/16/2025 03:59 PM EasternExtended Trading$4.12 -0.04 (-0.84%) As of 10/16/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADCT vs. COGT, TLRY, ABCL, IMCR, HROW, BHVN, EWTX, VCEL, GPCR, and HRMYShould you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Cogent Biosciences (COGT), Tilray Brands (TLRY), AbCellera Biologics (ABCL), Immunocore (IMCR), Harrow (HROW), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Vericel (VCEL), Structure Therapeutics (GPCR), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. ADC Therapeutics vs. Its Competitors Cogent Biosciences Tilray Brands AbCellera Biologics Immunocore Harrow Biohaven Edgewise Therapeutics Vericel Structure Therapeutics Harmony Biosciences Cogent Biosciences (NASDAQ:COGT) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings. Does the media favor COGT or ADCT? In the previous week, ADC Therapeutics had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 9 mentions for ADC Therapeutics and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.63 beat ADC Therapeutics' score of -0.10 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in COGT or ADCT? 41.1% of ADC Therapeutics shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer COGT or ADCT? Cogent Biosciences presently has a consensus target price of $19.67, indicating a potential upside of 20.21%. ADC Therapeutics has a consensus target price of $7.50, indicating a potential upside of 80.29%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 1 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.71ADC Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is COGT or ADCT more profitable? Cogent Biosciences has a net margin of 0.00% compared to ADC Therapeutics' net margin of -220.00%. ADC Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -223.82% -89.44% ADC Therapeutics -220.00%N/A -53.73% Which has more risk and volatility, COGT or ADCT? Cogent Biosciences has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Which has preferable earnings and valuation, COGT or ADCT? ADC Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$255.86M-$1.78-9.19ADC Therapeutics$70.84M6.61-$157.85M-$1.57-2.65 SummaryADC Therapeutics beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks. Get ADC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADCT vs. The Competition Export to ExcelMetricADC TherapeuticsMED IndustryMedical SectorNYSE ExchangeMarket Cap$479.25M$3.41B$6.09B$21.97BDividend YieldN/A2.29%5.73%3.59%P/E Ratio-2.6522.9385.0732.64Price / Sales6.61486.15604.9982.90Price / CashN/A46.9737.8624.53Price / Book-1.9810.5012.394.62Net Income-$157.85M-$52.47M$3.32B$1.01B7 Day Performance-9.37%-1.00%-0.24%-0.79%1 Month Performance25.68%14.49%9.56%0.25%1 Year Performance29.19%13.92%71.67%11.51% ADC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADCTADC Therapeutics2.256 of 5 stars$4.16-2.3%$7.50+80.3%+29.2%$479.25M$70.84M-2.65310News CoverageAnalyst ForecastCOGTCogent Biosciences1.8218 of 5 stars$15.90+0.9%$20.00+25.8%+44.1%$1.79BN/A-8.9380News CoverageAnalyst ForecastHigh Trading VolumeTLRYTilray Brands3.1996 of 5 stars$1.58-2.5%$1.94+22.6%-2.5%$1.78B$821.31M-0.682,842Trending NewsEarnings ReportOptions VolumeABCLAbCellera Biologics2.3363 of 5 stars$5.87-0.5%$8.00+36.3%+122.9%$1.76B$28.83M-10.67500IMCRImmunocore2.3337 of 5 stars$34.01-0.6%$56.89+67.3%+0.8%$1.72B$310.20M-85.03320HROWHarrow2.9582 of 5 stars$42.16-7.2%$68.50+62.5%-30.8%$1.68B$199.61M-168.64180High Trading VolumeBHVNBiohaven3.4178 of 5 stars$15.93+0.8%$48.85+206.6%-68.1%$1.67BN/A-2.08239EWTXEdgewise Therapeutics2.9432 of 5 stars$15.35-1.9%$38.83+153.0%-56.3%$1.65BN/A-9.9060VCELVericel3.3507 of 5 stars$33.74+4.0%$60.40+79.0%-15.8%$1.64B$237.22M281.19300Trending NewsAnalyst UpgradeAnalyst RevisionGPCRStructure Therapeutics3.4123 of 5 stars$28.68+5.1%$68.67+139.4%-29.3%$1.57BN/A-27.31136HRMYHarmony Biosciences4.7734 of 5 stars$26.59-2.5%$45.50+71.1%-25.5%$1.57B$714.73M8.58200Positive NewsAnalyst Forecast Related Companies and Tools Related Companies COGT Alternatives TLRY Alternatives ABCL Alternatives IMCR Alternatives HROW Alternatives BHVN Alternatives EWTX Alternatives VCEL Alternatives GPCR Alternatives HRMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ADCT) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADC Therapeutics SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ADC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
